Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products ...

And then there's what Van Kerkhove calls pre-symptomatic. These are people who've been infected, haven't yet gotten sick but will get sick.

MIAMI, July 29, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, ...

The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

Incidental and symptomatic patients did not differ with respect to mean age, sex, cancer type and stage, and risk factors for VTE. As a result from evolving treatment guidelines, approximately half of ...

Given that patients in the PV-P and PV-S subgroups did not statistically differ by risk category compared with their respectively control groups, the higher symptom score of patients in the PV-P and ...